UK Government Fund cornerstones £75M Advent Life Sciences fund
This article was originally published in Scrip
Advent Venture Partners has closed its first life sciences-focused venture capital fund at £75 million, with the UK Government's UK Future Technologies Fund investing £15 million in the round. Other limited partners in the fund wish to remain anonymous, Dr Shahzad Malik, General Partner, Advent Venture Partners, told Scrip. Dr Malik will co-manage the Advent Life Sciences fund with Advent General Partner Dr Raj Parekh.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.